RO7425781 clinical trials

An Open-label, Randomized Phase Ib/II Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma

This study is for people in the UK with multiple myeloma that has come back or not responded to previous treatments. It investigates new combinations of medications, including one called Forimtamig, to see how safe and effective they are.